scholarly journals Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer

2014 ◽  
pp. 1519 ◽  
Author(s):  
Shea Wilcox ◽  
Noel J Aherne ◽  
Linus C Benjamin ◽  
Bosco Wu ◽  
Thomaz de Campos Silva ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Intensity Modulated Radiotherapy ◽  
Androgen Deprivation ◽  
Long Term Outcomes ◽  
Image Guided ◽  
Intensity Modulated ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

scholarly journals Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
David Thomson ◽  
Sophie Merrick ◽  
Ric Swindell ◽  
Joanna Coote ◽  
Kay Kelly ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Intensity Modulated Radiotherapy ◽  
Progression Free Survival ◽  
Late Toxicity ◽  
Hypofractionated Radiotherapy ◽  
Intensity Modulated ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Background. The benefit of dose-escalated hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) in prostate cancer is not established. We report 5-year outcome and long-term toxicity data within a phase II clinical trial.Materials and Methods. 60 men with predominantly high-risk prostate cancer were treated. All patients received neoadjuvant hormone therapy, completing up to 6 months in total. Thirty patients were treated with 57 Gy in 19 fractions and 30 patients with 60 Gy in 20 fractions. Acute and 2-year toxicities were reported and patients followed longitudinally to assess 5 year outcomes and long-term toxicity. Toxicity was measured using RTOG criteria and LENT/SOMA questionnaire.Results. Median followup was 84 months. Five-year overall survival (OS) was 83% and biochemical progression-free survival (bPFS) was 50% for 57 Gy. Five-year OS was 75% and bPFS 58% for 60 Gy. At 7 years, toxicity by RTOG criteria was acceptable with no grade 3 or above toxicity. Compared with baseline, there was no significant change in urinary symptoms at 2 or 7 years. Bowel symptoms were stable between 2 and 7 years. All patients continued to have significant sexual dysfunction.Conclusion. In high-risk prostate cancer, dose-escalated hypofractionated radiotherapy using IMRT results in encouraging outcomes and acceptable late toxicity.

scholarly journals Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation

Cancer ◽  
2013 ◽  
Vol 119 (18) ◽  
pp. 3265-3271 ◽  
Author(s):  
Quynh-Nhu Nguyen ◽  
Lawrence B. Levy ◽  
Andrew K. Lee ◽  
Seungtaek S. Choi ◽  
Steven J. Frank ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
External Beam Radiotherapy ◽  
Androgen Deprivation ◽  
External Beam ◽  
Long Term Outcomes ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document